Thoratec Announces FDA Approval To Commence REVIVE-IT Study Utilizing HeartMate II®

    Thoratec Announces FDA Approval To Commence REVIVE-IT Study Utilizing
                                HeartMate II®

PR Newswire

PLEASANTON, Calif., Jan. 7, 2013

PLEASANTON, Calif., Jan. 7, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ:
THOR), a world leader in device-based mechanical circulatory support (MCS)
therapies to save, support and restore failing hearts, today announced that
the U.S. Food and Drug Administration (FDA) has granted an Investigational
Device Exemption (IDE) to commence the REVIVE-IT study utilizing the HeartMate
II® Left Ventricular Assist System.

REVIVE-IT (Randomized Evaluation of VAD InterVEntion before Inotropic Therapy)
is a prospective, randomized, controlled trial designed to compare the use of
the HeartMate II LVAD with optimal medical management (OMM) in patients with
New York Heart Association (NYHA) Class III heart failure. This feasibility
study is intended to provide initial scientific evidence regarding the
potential advantages of MCS therapy in treating earlier-stage, less ill heart
failure patients who are currently not indicated for LVAD support.

"IDE approval represents a significant milestone for REVIVE-IT, and we are
excited to move forward with this important study, which will allow us to
examine the use of LVAD technology earlier in the spectrum of heart failure,"
said Keith Aaronson, M.D., M.S., medical director of the heart transplant
program and Center for Circulatory Support at the University of Michigan
Cardiovascular Center (UM-CVC). Aaronson is serving as a co-principal
investigator for REVIVE-IT, along with Francis D. Pagani, M.D., Ph.D.,
surgical director of the heart transplant program and Center for Circulatory
Support at the UM-CVC, to whom the REVIVE-IT IDE was issued, and Robert
Kormos, M.D., director of the University of Pittsburgh Medical Center (UPMC)
Artificial Heart Program and co-director of the UPMC Heart Transplantation
Program.

The REVIVE-IT pilot study is designed to enroll up to 100 patients in NYHA
Class III heart failure from leading heart failure programs across the U.S.
Patients will receive either the HeartMate II LVAD or OMM (drug therapy). The
primary endpoint for the study is a composite measure of survival, freedom
from disabling stroke, and improvement in functional outcomes, as measured by
the six-minute walk test.

"REVIVE-IT will evaluate the use of the HeartMate II in heart failure patients
currently not indicated for LVAD support. These patients suffer from highly
impaired quality of life and functional capacity, but their disease has not
yet advanced to the point of more serious consequences, such as organ damage
or immobility," stated Dr. Kormos from UPMC.

The National Heart, Lung and Blood Institute (NHLBI) of the National
Institutes of Health and Thoratec are sponsoring the REVIVE-IT study, through
a $5 million contract from the NHLBI and a funding commitment of up to $11
million from Thoratec. The NHLBI is providing executive and scientific
guidance on the conduct of the study.

"We appreciate the leadership demonstrated by the NHLBI in this pioneering
study, as well as our partnership with Thoratec," said Dr. Pagani. "The
HeartMate II device has been extensively studied for long-term support of
advanced heart failure patients and has a very well-defined efficacy and
safety profile. We look forward to exploring its utilization and potential
benefits, including extended survival and improved functional status, in
earlier-stage patients."

In addition to REVIVE-IT, Thoratec maintains a firm commitment to the
completion of the ongoing ROADMAP (Risk Assessment and Comparative
Effectiveness Of Left Ventricular Assist Device and Medical Management in
Ambulatory Heart Failure Patients) study. "ROADMAP and REVIVE-IT are
complementary studies which together should advance the field's understanding
of LVAD therapy in Class III and earlier-stage Class IV heart failure
patients," stated David Farrar, Ph.D., Vice President, Research and Scientific
Affairs at Thoratec. ROADMAP is a post-market study of the HeartMate II,
involving ambulatory advanced heart failure patients who are not yet dependent
on intravenous inotropic support and are typically categorized as INTERMACS
profiles 4-6, within the existing FDA-approved indication for Destination
Therapy, whereas REVIVE-IT will include Class III patients currently not
approved for LVAD support. As of the end of 2012, 90 patients have been
enrolled in ROADMAP, and Thoratec expects the full cohort of 200 patients to
be enrolled by the end of 2013.

"Thoratec's mission is to advance the treatment of heart failure and the field
of mechanical circulatory support. To that end, we are pleased to partner
with preeminent VAD programs across the U.S., under the leadership of the
UM-CVC and UPMC, in the REVIVE-IT study," commented Gary F. Burbach, President
and Chief Executive Officer of Thoratec.

For more information regarding the REVIVE-IT study, visit
http://clinicaltrials.gov ID# NCT01369407. Given the change in sponsorship of
the study, however, some information on this website is subject to change,
including information about the study device as well as the investigational
sites that will be participating in the study. For more information regarding
the ROADMAP study, visit http://clinicaltrials.gov ID# NCT01452802.

About HeartMate II
The HeartMate II is intended for a broad range of advanced heart failure
patients and is the only continuous-flow left ventricular assist device (LVAD)
approved by the FDA for both Bridge to Transplantation and Destination
Therapy. The device is designed to provide long-term cardiac support, pumping
up to 10 liters of blood per minute for full support of the circulation, or to
supplement the native function of the patient's left ventricle. The HeartMate
II is placed just below the diaphragm and is connected to the left ventricle,
returning blood flow to the aorta, the main artery that carries oxygenated
blood to the entire body. With only one moving part, a continuously spinning
rotor, HeartMate II is designed to provide exceptional reliability. An
external, wearable system that includes a small controller and two batteries
is attached by a percutaneous driveline. More than 200 peer-reviewed
publications have featured studies regarding the HeartMate II, far exceeding
the volume of published data on all other LVADs combined. To date, over
13,000 patients have been implanted with the HeartMate II, including over
5,500 currently on support.

About Thoratec
Thoratec is the world leader in mechanical circulatory support with the
broadest product portfolio to treat the full range of clinical needs for
patients suffering from advanced heart failure. The company's products include
the HeartMate LVAS and Thoratec VAD, with more than 20,000 devices implanted
in patients suffering from heart failure. Thoratec also manufactures and
distributes the CentriMag and PediMag / PediVAS product lines. Thoratec is
headquartered in Pleasanton, California. For more information, visit
www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered
trademarks of Thoratec Corporation and IVAD, Thoratec 360, Shared Care and
Thoratec Connect are trademarks of Thoratec Corporation. CentriMag and
PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered
trademark of Thoratec Switzerland GmbH.

Many of the preceding paragraphs, particularly but not exclusively those
addressing guidance for fiscal 2012 financial results or future performance
contain forward-looking statements within the meaning of Sections 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
These statements can be identified by the words, "believes," "views,"
"expects," "plans," "projects," "hopes," "could," "will," and other similar
words. Actual results, events or performance could differ materially from
these forward-looking statements based on a variety of factors, many of which
are beyond Thoratec's control. Therefore, readers are cautioned not to put
undue reliance on these statements. Investors are cautioned that all such
statements involve risks and uncertainties, including risks related to
regulatory approvals, the development of new products and new markets
including Destination Therapy, the growth of existing markets for our
products, customer and physician acceptance of Thoratec products, the effects
of FDA regulatory requirements, our ability to address issues raised by FDA
inspections adequately and on a timely basis without a resulting recall of
products or interruption of manufacturing or shipment of products, the effects
of healthcare reimbursement and coverage policies, and the effects of
competition. Forward-looking statements contained in this press release should
be considered in light these factors and those factors discussed from time to
time in Thoratec's public reports filed with the Securities and Exchange
Commission, such as those discussed under the heading, "Risk Factors," in
Thoratec's most recent annual report on Form 10-K, quarterly reports on Form
10-Q, current reports on Form 8-K and other SEC filings. These forward-looking
statements speak only as of the date hereof. Thoratec undertakes no obligation
to publicly release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances after the date
hereof, or to reflect the occurrence of unanticipated events.

SOURCE Thoratec Corporation

Website: http://www.thoratec.com
Contact: Susan Benton Russell, Benton Communications, +1-310-697-3488
 
Press spacebar to pause and continue. Press esc to stop.